Skip to main content

Table 1 Clinicopathological characteristics of 300 cases of duodenal GISTs

From: Clinicopathological features, surgical strategy and prognosis of duodenal gastrointestinal stromal tumors: a series of 300 patients

Characteristics Parameters
Age (∑ = 267)
  ≤ 60 161 (60.3%)
  > 60 106 (39.7%)
Gender (∑ = 291)
 Male 143 (49.1%)
 Female 148 (50.8%)
Symptoms (∑ = 300)
 Bleeding or anemia 128 (42.7%)
 Abdominal pain 56 (18.7%)
 Abdominal mass 11 (3.7%)
 Abdominal discomfort 11 (3.7%)
 Anorexia 6 (2.0%)
 Othersaa 36 (12.0%)
Anatomical location (∑ = 266)
 Superior portion 42 (15.8%)
 Descending portion 137 (51.5%)
 Horizontal portion 65 (24.4%)
 Ascending portion 22 (8.3%)
Surgical procedure (∑ = 300)
 Limited resection* 199 (66.3%)
 Pancreaticoduodenectomy 78 (26.0%)
 Not available 13 (4.3%)
 No surgery 10 (3.3%)
Resection margin (∑ = 300)
 R0 275 (91.7%)
 R1/2 2 (0.7%)
 Not available/No surgery 23 (7.7%)
Tumor size (∑ = 277)
  ≤ 2 cm 34 (12.3%)
 2–5 cm 135 (48.7%)
 5–10 cm 73 (26.4%)
  > 10 cm 35 (12.6%)
Mitotic index (∑ = 240)
  ≤ 5 181 (75.4%)
  > 5 59 (24.6%)
Morphology (∑ = 160)
 Spindle 148 (92.5%)
 Epithelioid 1 (0.6%)
 Mixed 11 (6.9%)
Immunohistochemistry
 CD117 (∑ = 288) 284 (98.6%)
 DOG-1 (∑ = 41) 40 (97.6%)
 CD34 (∑ = 167) 126 (75.4%)
Genomic mutation (∑ = 41)
 KIT 31 (75.6%)
 PDGFRA 1 (2.4%)
 KIT and PDGFRA 5 (12.2%)
 Wild type 4 (9.8%)
NIH risk category (∑ = 258)
 Very low 25 (9.7%)
 Low 104 (40.3%)
 Intermediate 2 (0.8%)
 High 127 (49.2%)
Neoadjuvant therapy (∑ = 300)
 No 287 (95.7%)
 Yes 13 (4.3%)
Adjuvant therapy (∑ = 300)
 No 263 (87.7%)
 Yes 37 (12.3%)
Follow-up (∑ = 202, month)
 Mean ± SD 39.3 ± 39.4
 Median (range) 25.0 (13.0, 58.5)
Survival rate (∑ = 202)
 1−/3−/5−/10-year DFS 94.4%/75.2%/64.4%/46.5%
 1−/3−/5−/10-year DSS 99.5%/93.4%/80.9%/54.5%
  1. aLimited resection included wedge resection, segmental resection or enucleation
  2. GIST: gastrointestinal stromal tumor; NIH: National Institutes of Health; SD: standard deviation